文献速递复苏、休克与脓毒症

血管加压素、类固醇与肾上腺素三联疗法在心脏骤停中的疗效:随机对照试验的系统评价与荟萃分析

Efficacy of combination triple therapy with vasopressin, steroid, and epinephrine in cardiac arrest: a systematic review and meta-analysis of randomized-controlled trials.
PubMed 文献 · J Intensive Care · 2022-02-02
一句话结论院内心脏骤停中,血管加压素、类固醇与肾上腺素三联疗法与自主循环恢复增加相关(OR 2.281),但出院生存率无显著差异。

本系统评价与荟萃分析纳入3项临床试验,探讨血管加压素、类固醇与肾上腺素(VSE)三联疗法对院内心脏骤停(IHCA)复苏期间及之后院内生存和自主循环恢复(ROSC)的影响。汇总分析显示VSE与IHCA患者ROSC增加显著相关(OR 2.281,95%CI 1.304-3.989,P=0.004)。两项研究(368例)的荟萃分析显示,复苏期间及复苏后15-20分钟平均动脉压下降幅度、无肾衰竭天数和无凝血衰竭天数均有显著差异。但出院生存率(OR 2.082,95%CI 0.638-6.796,P=0.225)和無呼吸机天数(SMD 0.201,95%CI -0.677至1.079天,P=0.838)无显著差异。

要点

  • IHCA患者中,VSE三联疗法与ROSC增加显著相关(OR 2.281,95%CI 1.304-3.989,P=0.004)。
  • 两项研究(368例)显示,VSE组复苏期间及复苏后15-20分钟平均动脉压下降幅度有显著差异(SMD 1.069,95%CI 0.851-1.288,P<0.001)。
  • 无肾衰竭天数(SMD 0.590,95%CI 0.312-0.869天,P<0.001)和无凝血衰竭天数(SMD 0.403,95%CI 0.128-0.679,P=0.004)在VSE组有显著差异。
  • 出院生存率无显著差异(OR 2.082,95%CI 0.638-6.796,P=0.225)。
  • 無呼吸机天数无显著差异(SMD 0.201,95%CI -0.677至1.079天,P=0.838)。

适用人群与场景

  • 院内心脏骤停(IHCA)患者,复苏期间及复苏后。

研究设计与关键结果

  • 研究类型:随机对照试验的系统评价与荟萃分析;纳入3项临床试验;检索数据库从建库至2021年10月。
  • 主要终点:VSE与IHCA患者ROSC增加显著相关(OR 2.281,95%CI 1.304-3.989,P=0.004)。
  • 两项研究(368例)的荟萃分析:复苏期间及复苏后15-20分钟平均动脉压下降幅度有显著差异(SMD 1.069,95%CI 0.851-1.288,P<0.001)。
  • 无肾衰竭天数有显著差异(SMD 0.590,95%CI 0.312-0.869天,P<0.001)。
  • 无凝血衰竭天数有显著差异(SMD 0.403,95%CI 0.128-0.679,P=0.004)。
  • 出院生存率无显著差异(OR 2.082,95%CI 0.638-6.796,P=0.225)。
  • 無呼吸机天数无显著差异(SMD 0.201,95%CI -0.677至1.079天,P=0.838)。

证据类型、等级与局限

  • 证据类型:随机对照试验的系统评价与荟萃分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,IHCA期间及之后使用VSE联合治疗可能在ROSC、无肾衰竭和无循环衰竭天数以及平均动脉压方面有益。

指南或共识出处

  • Prospero注册号:CRD42020178297(2020年5月7日)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: This study investigated whether combination therapy with vasopressin, steroid, and epinephrine (VSE) improves in-hospital survival and return of spontaneous circulation (ROSC) during and after resuscitation in-hospital cardiac arrest (CA).

MATERIALS AND METHODS: Various databases were explored from inception until October 2021 for relevant published clinical trials and cohort studies.

RESULTS: Three clinical trials were included. Pooled analysis suggested that VSE was significantly associated with increased ROSC in patients with in-hospital CA (IHCA) (odds ratio (OR): 2.281, 95% confidence interval (CI): 1.304-3.989, P value = 0.004). Meta-analysis of two studies (368 patients) demonstrated a significant difference in the reduction of mean arterial pressure (MAP) during and 15-20 min after cardiopulmonary resuscitation (standardized mean difference (SMD): 1.069, 95% CI: 0.851-1.288, P value < 0.001), renal failure free days (SMD = 0.590; 95% CI: 0.312-0.869 days; P value < 0.001), and coagulation failure free days (SMD = 0.403; 95% CI: 0.128-0.679, P value = 0.004). However, no significant difference was observed for survival-to-discharge ratio (OR: 2.082, 95% CI: 0.638-6.796, P value = 0.225) and ventilator free days (SMD = 0.201, 95% CI: - 0.677, 1.079 days; P value = 0.838).

CONCLUSIONS: VSE combination therapy during and after IHCA may have beneficial effects in terms of the ROSC, renal and circulatory failure free days, and MAP. Prospero registration: CRD42020178297 (05/07/2020).

来源:J Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Saghafi F, Bagheri N, Salehi-Abargouei A, et al. Efficacy of combination triple therapy with vasopressin, steroid, and epinephrine in cardiac arrest: a systematic review and meta-analysis of randomized-controlled trials. J Intensive Care. 2022. PMID: 35109925. doi:10.1186/s40560-022-00597-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。